{"id":19165,"date":"2024-05-04T15:39:27","date_gmt":"2024-05-04T19:39:27","guid":{"rendered":"https:\/\/www.progeriaresearch.org\/?p=19165"},"modified":"2025-01-29T09:23:02","modified_gmt":"2025-01-29T14:23:02","slug":"sentynl","status":"publish","type":"post","link":"https:\/\/www.progeriaresearch.org\/uk\/2024\/05\/04\/sentynl\/","title":{"rendered":"\u0417\u0430\u0440\u0430\u0437 PRF \u0441\u043f\u0456\u0432\u043f\u0440\u0430\u0446\u044e\u0454 \u0437 Sentynl Therapeutics, \u043d\u043e\u0432\u0438\u043c \u0433\u043b\u043e\u0431\u0430\u043b\u044c\u043d\u0438\u043c \u0432\u043b\u0430\u0441\u043d\u0438\u043a\u043e\u043c \u043b\u0456\u043a\u0443\u0432\u0430\u043d\u043d\u044f \u043b\u043e\u043d\u0430\u0444\u0430\u0440\u043d\u0456\u0431\u043e\u043c (Zokinvy\u00a9)"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;4.16&#8243; global_colors_info=&#8221;{}&#8221;][et_pb_row _builder_version=&#8221;4.16&#8243; background_size=&#8221;initial&#8221; background_position=&#8221;top_left&#8221; background_repeat=&#8221;repeat&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.16&#8243; custom_padding=&#8221;|||&#8221; global_colors_info=&#8221;{}&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_image src=&#8221;https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2024\/05\/static1.squarespace.webp&#8221; title_text=&#8221;static1.squarespace&#8221; url=&#8221;https:\/\/www.charitynavigator.org\/ein\/043460220&#8243; align=&#8221;center&#8221; admin_label=&#8221;Sentynl&#8221; _builder_version=&#8221;4.24.3&#8243; _module_preset=&#8221;default&#8221; width=&#8221;50%&#8221; max_width=&#8221;50%&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_image][et_pb_text _builder_version=&#8221;4.24.3&#8243; text_font_size=&#8221;18px&#8221; background_size=&#8221;initial&#8221; background_position=&#8221;top_left&#8221; background_repeat=&#8221;repeat&#8221; global_colors_info=&#8221;{}&#8221;]<\/p>\n<p>\u0414\u0456\u0454 \u0432 \u043f&#039;\u044f\u0442\u043d\u0438\u0446\u044e, 3 \u0442\u0440\u0430\u0432\u043d\u044f<sup>rd<\/sup>, 2024, <a href=\"https:\/\/url2.mailanyone.net\/scanner?m=1rzcKM-0009Dy-3G&amp;d=4%7Cmail%2F90%2F1713963600%2F1rzcKM-0009Dy-3G%7Cin2m%7C57e1b682%7C18374732%7C14629442%7C662903CE3D97FA99FA9E3F52842D032F&amp;o=%2Fphte%3A%2Fstsonnt%2F.cmyl&amp;s=pj636_P9eRvPUtyP8VtSjuVNKfg\">Sentynl Therapeutics, Inc.<\/a> (Sentynl), \u0430\u043c\u0435\u0440\u0438\u043a\u0430\u043d\u0441\u044c\u043a\u0430 \u0431\u0456\u043e\u0444\u0430\u0440\u043c\u0430\u0446\u0435\u0432\u0442\u0438\u0447\u043d\u0430 \u043a\u043e\u043c\u043f\u0430\u043d\u0456\u044f, \u0449\u043e \u043f\u043e\u0432\u043d\u0456\u0441\u0442\u044e \u043d\u0430\u043b\u0435\u0436\u0438\u0442\u044c Zydus Lifesciences, Ltd, \u043f\u0440\u0438\u0434\u0431\u0430\u043b\u0430 \u0433\u043b\u043e\u0431\u0430\u043b\u044c\u043d\u0456 \u043f\u0440\u0430\u0432\u0430 \u043d\u0430 \u043b\u043e\u043d\u0430\u0444\u0430\u0440\u043d\u0456\u0431 (Zokinvy) \u0443 Eiger BioPharmaceuticals (Eiger). Zokinvy\u00ae \u043d\u0430\u0434\u0430\u0454\u0442\u044c\u0441\u044f \u0441\u0456\u043c\u2019\u044f\u043c \u0443 \u0432\u0441\u044c\u043e\u043c\u0443 \u0441\u0432\u0456\u0442\u0456, \u044f\u043a\u0456 \u0432\u0438\u043a\u043e\u0440\u0438\u0441\u0442\u043e\u0432\u0443\u044e\u0442\u044c \u043f\u0440\u0435\u043f\u0430\u0440\u0430\u0442 \u0434\u043b\u044f \u043b\u0456\u043a\u0443\u0432\u0430\u043d\u043d\u044f \u043f\u0440\u043e\u0433\u0435\u0440\u0456\u0457.<\/p>\n<p>\u041a\u043e\u043c\u043f\u0430\u043d\u0456\u044f Sentynl, \u0440\u043e\u0437\u0442\u0430\u0448\u043e\u0432\u0430\u043d\u0430 \u0432 \u0421\u0430\u043d-\u0414\u0456\u0454\u0433\u043e, \u041a\u0430\u043b\u0456\u0444\u043e\u0440\u043d\u0456\u044f, \u0437\u043e\u0441\u0435\u0440\u0435\u0434\u0436\u0435\u043d\u0430 \u043d\u0430 \u043f\u043e\u0441\u0442\u0430\u0447\u0430\u043d\u043d\u0456 \u043d\u043e\u0432\u0438\u0445 \u0431\u0456\u043e\u0444\u0430\u0440\u043c\u0430\u0446\u0435\u0432\u0442\u0438\u0447\u043d\u0438\u0445 \u043b\u0456\u043a\u0456\u0432, \u044f\u043a\u0456 \u043f\u0440\u043e\u0434\u043e\u0432\u0436\u0443\u044e\u0442\u044c, \u043f\u043e\u043a\u0440\u0430\u0449\u0443\u044e\u0442\u044c \u0430\u0431\u043e \u043f\u043e\u043a\u0440\u0430\u0449\u0443\u044e\u0442\u044c \u0436\u0438\u0442\u0442\u044f \u043b\u044e\u0434\u0435\u0439 \u0437 \u0440\u0456\u0434\u043a\u0456\u0441\u043d\u0438\u043c\u0438 \u0437\u0430\u0445\u0432\u043e\u0440\u044e\u0432\u0430\u043d\u043d\u044f\u043c\u0438 (https:\/\/sentynl.com\/). PRF \u0432\u0434\u044f\u0447\u043d\u0438\u0439 \u0437\u0430 \u0443\u0441\u043f\u0456\u0448\u043d\u0435 \u043f\u0430\u0440\u0442\u043d\u0435\u0440\u0441\u0442\u0432\u043e \u0437 Eiger \u0456 \u0440\u0430\u0434\u0438\u0439 \u043e\u0431\u2019\u0454\u0434\u043d\u0430\u0442\u0438 \u0437\u0443\u0441\u0438\u043b\u043b\u044f \u0437 Sentynl. PRF \u0431\u0443\u0434\u0435 \u0442\u0456\u0441\u043d\u043e \u0441\u043f\u0456\u0432\u043f\u0440\u0430\u0446\u044e\u0432\u0430\u0442\u0438 \u0437 \u043d\u0438\u043c\u0438, \u044f\u043a \u043c\u0438 \u0446\u0435 \u0440\u043e\u0431\u0438\u043b\u0438 \u0437 Eiger, \u0449\u043e\u0431 \u0434\u043e\u043f\u043e\u043c\u043e\u0433\u0442\u0438 \u043a\u043e\u043c\u043f\u0430\u043d\u0456\u0457 \u0432 \u0437\u0443\u0441\u0438\u043b\u043b\u044f\u0445 \u0437\u0430\u0431\u0435\u0437\u043f\u0435\u0447\u0438\u0442\u0438 \u0431\u0435\u0437\u043f\u0435\u0440\u0435\u0431\u0456\u0439\u043d\u0435 \u043f\u043e\u0441\u0442\u0430\u0447\u0430\u043d\u043d\u044f Zokinvy \u0434\u043b\u044f \u043f\u0430\u0446\u0456\u0454\u043d\u0442\u0456\u0432 \u0443 \u0432\u0441\u044c\u043e\u043c\u0443 \u0441\u0432\u0456\u0442\u0456.\u00a0\u00a0<\/p>\n<p>\u041f\u043e\u0441\u0438\u043b\u0430\u043d\u043d\u044f \u043d\u0430 \u043f\u0440\u0435\u0441-\u0440\u0435\u043b\u0456\u0437 Sentynl \u0449\u043e\u0434\u043e \u0446\u0456\u0454\u0457 \u043d\u043e\u0432\u0438\u043d\u0438 \u043c\u043e\u0436\u043d\u0430 \u0437\u043d\u0430\u0439\u0442\u0438 <a href=\"https:\/\/www.prnewswire.com\/news-releases\/sentynl-therapeutics-announces-global-acquisition-of-zokinvy-lonafarnib-for-treatment-of-hutchinson-gilford-progeria-syndrome-from-eiger-biopharmaceuticals-302135968.html\">\u0442\u0443\u0442<\/a>.<\/p>\n<p>&nbsp;<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>","protected":false},"excerpt":{"rendered":"<p>\u041f\u043e\u0447\u0438\u043d\u0430\u044e\u0447\u0438 \u0437 \u043f\u2019\u044f\u0442\u043d\u0438\u0446\u0456, 3 \u0442\u0440\u0430\u0432\u043d\u044f, Sentynl Therapeutics \u0432\u0456\u0434\u043f\u043e\u0432\u0456\u0434\u0430\u0454 \u0437\u0430 \u0432\u0438\u0440\u043e\u0431\u043d\u0438\u0446\u0442\u0432\u043e \u0442\u0430 \u0440\u043e\u0437\u043f\u043e\u0432\u0441\u044e\u0434\u0436\u0435\u043d\u043d\u044f Zokinvy, \u0441\u0445\u0432\u0430\u043b\u0435\u043d\u043e\u0433\u043e FDA \u043f\u0440\u0435\u043f\u0430\u0440\u0430\u0442\u0443 \u0434\u043b\u044f \u043b\u0456\u043a\u0443\u0432\u0430\u043d\u043d\u044f \u043f\u0440\u043e\u0433\u0435\u0440\u0456\u0457. <\/p>","protected":false},"author":2,"featured_media":18808,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":"","_links_to":"","_links_to_target":""},"categories":[2,1],"tags":[],"class_list":["post-19165","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Sentynl I The Progeria esearch Foundation<\/title>\n<meta name=\"description\" content=\"Effective Friday, May 3, Sentynl Therapeutics is responsible for the manufacture and distribution of Zokinvy, the FDA-approved treatment for Progeria.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.progeriaresearch.org\/uk\/2024\/05\/04\/sentynl\/\" \/>\n<meta property=\"og:locale\" content=\"uk_UA\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Sentynl I The Progeria esearch Foundation\" \/>\n<meta property=\"og:description\" content=\"Effective Friday, May 3, Sentynl Therapeutics is responsible for the manufacture and distribution of Zokinvy, the FDA-approved treatment for Progeria.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.progeriaresearch.org\/uk\/2024\/05\/04\/sentynl\/\" \/>\n<meta property=\"og:site_name\" content=\"The Progeria Research Foundation\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ProgeriaResearch\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-05-04T19:39:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-29T14:23:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2024\/05\/sentynl-square-logo.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"200\" \/>\n\t<meta property=\"og:image:height\" content=\"200\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Karen Betournay\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@Progeria\" \/>\n<meta name=\"twitter:site\" content=\"@Progeria\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Karen Betournay\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 \u0445\u0432\u0438\u043b\u0438\u043d\u0430\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/\"},\"author\":{\"name\":\"Karen Betournay\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946\"},\"headline\":\"PRF now collaborating with Sentynl Therapeutics, new global owner of lonafarnib treatment (Zokinvy\u00a9)\",\"datePublished\":\"2024-05-04T19:39:27+00:00\",\"dateModified\":\"2025-01-29T14:23:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/\"},\"wordCount\":266,\"publisher\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2024\/05\/sentynl-square-logo.jpeg\",\"articleSection\":[\"News\",\"Uncategorized\"],\"inLanguage\":\"uk\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/\",\"url\":\"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/\",\"name\":\"Sentynl I The Progeria esearch Foundation\",\"isPartOf\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2024\/05\/sentynl-square-logo.jpeg\",\"datePublished\":\"2024-05-04T19:39:27+00:00\",\"dateModified\":\"2025-01-29T14:23:02+00:00\",\"description\":\"Effective Friday, May 3, Sentynl Therapeutics is responsible for the manufacture and distribution of Zokinvy, the FDA-approved treatment for Progeria.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#breadcrumb\"},\"inLanguage\":\"uk\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"uk\",\"@id\":\"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#primaryimage\",\"url\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2024\/05\/sentynl-square-logo.jpeg\",\"contentUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2024\/05\/sentynl-square-logo.jpeg\",\"width\":200,\"height\":200},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.progeriaresearch.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"PRF now collaborating with Sentynl Therapeutics, new global owner of lonafarnib treatment (Zokinvy\u00a9)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#website\",\"url\":\"https:\/\/www.progeriaresearch.org\/ta\/\",\"name\":\"The Progeria Research Foundation\",\"description\":\"For the Children \u2665 For the Cure\",\"publisher\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.progeriaresearch.org\/ta\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"uk\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#organization\",\"name\":\"The Progeria Research Foundation\",\"url\":\"https:\/\/www.progeriaresearch.org\/ta\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"uk\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png\",\"contentUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png\",\"width\":300,\"height\":86,\"caption\":\"The Progeria Research Foundation\"},\"image\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/ProgeriaResearch\/\",\"https:\/\/x.com\/Progeria\",\"https:\/\/www.instagram.com\/progeriaresearch\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946\",\"name\":\"Karen Betournay\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"uk\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g\",\"caption\":\"Karen Betournay\"},\"url\":\"https:\/\/www.progeriaresearch.org\/uk\/author\/karenb\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Sentynl I The Progeria esearch Foundation","description":"\u041f\u043e\u0447\u0438\u043d\u0430\u044e\u0447\u0438 \u0437 \u043f\u2019\u044f\u0442\u043d\u0438\u0446\u0456, 3 \u0442\u0440\u0430\u0432\u043d\u044f, Sentynl Therapeutics \u0432\u0456\u0434\u043f\u043e\u0432\u0456\u0434\u0430\u0454 \u0437\u0430 \u0432\u0438\u0440\u043e\u0431\u043d\u0438\u0446\u0442\u0432\u043e \u0442\u0430 \u0440\u043e\u0437\u043f\u043e\u0432\u0441\u044e\u0434\u0436\u0435\u043d\u043d\u044f Zokinvy, \u0441\u0445\u0432\u0430\u043b\u0435\u043d\u043e\u0433\u043e FDA \u043f\u0440\u0435\u043f\u0430\u0440\u0430\u0442\u0443 \u0434\u043b\u044f \u043b\u0456\u043a\u0443\u0432\u0430\u043d\u043d\u044f \u043f\u0440\u043e\u0433\u0435\u0440\u0456\u0457.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.progeriaresearch.org\/uk\/2024\/05\/04\/sentynl\/","og_locale":"uk_UA","og_type":"article","og_title":"Sentynl I The Progeria esearch Foundation","og_description":"Effective Friday, May 3, Sentynl Therapeutics is responsible for the manufacture and distribution of Zokinvy, the FDA-approved treatment for Progeria.","og_url":"https:\/\/www.progeriaresearch.org\/uk\/2024\/05\/04\/sentynl\/","og_site_name":"The Progeria Research Foundation","article_publisher":"https:\/\/www.facebook.com\/ProgeriaResearch\/","article_published_time":"2024-05-04T19:39:27+00:00","article_modified_time":"2025-01-29T14:23:02+00:00","og_image":[{"width":200,"height":200,"url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2024\/05\/sentynl-square-logo.jpeg","type":"image\/jpeg"}],"author":"Karen Betournay","twitter_card":"summary_large_image","twitter_creator":"@Progeria","twitter_site":"@Progeria","twitter_misc":{"Written by":"Karen Betournay","Est. reading time":"1 \u0445\u0432\u0438\u043b\u0438\u043d\u0430"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#article","isPartOf":{"@id":"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/"},"author":{"name":"Karen Betournay","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946"},"headline":"PRF now collaborating with Sentynl Therapeutics, new global owner of lonafarnib treatment (Zokinvy\u00a9)","datePublished":"2024-05-04T19:39:27+00:00","dateModified":"2025-01-29T14:23:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/"},"wordCount":266,"publisher":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#primaryimage"},"thumbnailUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2024\/05\/sentynl-square-logo.jpeg","articleSection":["News","Uncategorized"],"inLanguage":"uk"},{"@type":"WebPage","@id":"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/","url":"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/","name":"Sentynl I The Progeria esearch Foundation","isPartOf":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#primaryimage"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#primaryimage"},"thumbnailUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2024\/05\/sentynl-square-logo.jpeg","datePublished":"2024-05-04T19:39:27+00:00","dateModified":"2025-01-29T14:23:02+00:00","description":"\u041f\u043e\u0447\u0438\u043d\u0430\u044e\u0447\u0438 \u0437 \u043f\u2019\u044f\u0442\u043d\u0438\u0446\u0456, 3 \u0442\u0440\u0430\u0432\u043d\u044f, Sentynl Therapeutics \u0432\u0456\u0434\u043f\u043e\u0432\u0456\u0434\u0430\u0454 \u0437\u0430 \u0432\u0438\u0440\u043e\u0431\u043d\u0438\u0446\u0442\u0432\u043e \u0442\u0430 \u0440\u043e\u0437\u043f\u043e\u0432\u0441\u044e\u0434\u0436\u0435\u043d\u043d\u044f Zokinvy, \u0441\u0445\u0432\u0430\u043b\u0435\u043d\u043e\u0433\u043e FDA \u043f\u0440\u0435\u043f\u0430\u0440\u0430\u0442\u0443 \u0434\u043b\u044f \u043b\u0456\u043a\u0443\u0432\u0430\u043d\u043d\u044f \u043f\u0440\u043e\u0433\u0435\u0440\u0456\u0457.","breadcrumb":{"@id":"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#breadcrumb"},"inLanguage":"uk","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/"]}]},{"@type":"ImageObject","inLanguage":"uk","@id":"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#primaryimage","url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2024\/05\/sentynl-square-logo.jpeg","contentUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2024\/05\/sentynl-square-logo.jpeg","width":200,"height":200},{"@type":"BreadcrumbList","@id":"https:\/\/www.progeriaresearch.org\/2024\/05\/04\/sentynl\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.progeriaresearch.org\/"},{"@type":"ListItem","position":2,"name":"PRF now collaborating with Sentynl Therapeutics, new global owner of lonafarnib treatment (Zokinvy\u00a9)"}]},{"@type":"WebSite","@id":"https:\/\/www.progeriaresearch.org\/ta\/#website","url":"https:\/\/www.progeriaresearch.org\/ta\/","name":"\u0414\u043e\u0441\u043b\u0456\u0434\u043d\u0438\u0446\u044c\u043a\u0438\u0439 \u0444\u043e\u043d\u0434 Progeria","description":"\u0414\u043b\u044f \u0434\u0456\u0442\u0435\u0439 \u2665 \u0414\u043b\u044f \u043b\u0456\u043a\u0443\u0432\u0430\u043d\u043d\u044f","publisher":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.progeriaresearch.org\/ta\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"uk"},{"@type":"Organization","@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization","name":"\u0414\u043e\u0441\u043b\u0456\u0434\u043d\u0438\u0446\u044c\u043a\u0438\u0439 \u0444\u043e\u043d\u0434 Progeria","url":"https:\/\/www.progeriaresearch.org\/ta\/","logo":{"@type":"ImageObject","inLanguage":"uk","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/","url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png","contentUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png","width":300,"height":86,"caption":"The Progeria Research Foundation"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ProgeriaResearch\/","https:\/\/x.com\/Progeria","https:\/\/www.instagram.com\/progeriaresearch\/"]},{"@type":"Person","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946","name":"\u041a\u0430\u0440\u0435\u043d \u0411\u0435\u0442\u0443\u0440\u043d\u0435","image":{"@type":"ImageObject","inLanguage":"uk","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g","caption":"Karen Betournay"},"url":"https:\/\/www.progeriaresearch.org\/uk\/author\/karenb\/"}]}},"_links":{"self":[{"href":"https:\/\/www.progeriaresearch.org\/uk\/wp-json\/wp\/v2\/posts\/19165","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.progeriaresearch.org\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.progeriaresearch.org\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/uk\/wp-json\/wp\/v2\/comments?post=19165"}],"version-history":[{"count":0,"href":"https:\/\/www.progeriaresearch.org\/uk\/wp-json\/wp\/v2\/posts\/19165\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/uk\/wp-json\/wp\/v2\/media\/18808"}],"wp:attachment":[{"href":"https:\/\/www.progeriaresearch.org\/uk\/wp-json\/wp\/v2\/media?parent=19165"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/uk\/wp-json\/wp\/v2\/categories?post=19165"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/uk\/wp-json\/wp\/v2\/tags?post=19165"}],"curies":[{"name":"\u0412\u041f","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}